UT Health San Antonio to lead $11 million, NIH-funded study of a first-ever oral chlamydia vaccine
SAN ANTONIO, May 9, 2024 /PRNewswire-PRWeb/ -- A research team led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been awarded approximately $11 million over five years by the National Institutes of Health to study a first-ever chlamydia vaccine.
- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) will direct a team of researchers to investigate a novel oral vaccine for chlamydia, the most reported sexually transmitted disease, with funding from the National Institutes of Health.
- SAN ANTONIO, May 9, 2024 /PRNewswire-PRWeb/ -- A research team led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been awarded approximately $11 million over five years by the National Institutes of Health to study a first-ever chlamydia vaccine.
- The UT Health San Antonio-led study of a novel oral vaccine that could protect against chlamydia infection is being funded through a cooperative agreements research project grant, known as a U01 grant.
- Back in 2022, UT Health San Antonio was granted an exclusive global license to allow Ohio biopharmaceutical company Blue Water Vaccines Inc. to develop Zhong's findings into an oral vaccine for chlamydia.